Literature DB >> 3106482

Differential ability of human immunodeficiency virus isolates to productively infect human cells.

L A Evans, T M McHugh, D P Stites, J A Levy.   

Abstract

Isolates of HIV showed distinct differences in the ability to replicate in continuous human hematopoietic cell lines. Moreover, although all PMC cultures obtained from healthy individuals could be infected with HIV, considerable variation in the amount of virus released from different PMC cultures was observed. These biological properties of HIV could not be correlated with clinical state, binding properties of the virus isolates to target cells, or differences in target cell CD4 antigen expression. Some isolates of HIV that could not directly infect the HUT-78 cell line showed productive infection when PMC infected with these viruses were added to this human T cell line. These observations emphasize the importance of cell to cell contact in the spread of virus. The results demonstrate for the first time the differences in the host range specificity of HIV isolates in several individual PMC cultures, and indicate that the optimal isolation of HIV is achieved with normal human PMC rather than established human cell lines.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3106482

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  53 in total

1.  Distinct human immunodeficiency virus strains in the bone marrow are associated with the development of thrombocytopenia.

Authors:  F Voulgaropoulou; B Tan; M Soares; B Hahn; L Ratner
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

2.  Do beta-chemokines have clinical relevance in HIV infection?

Authors:  C E Mackewicz; E Barker; G Greco; G Reyes-Teran; J A Levy
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

3.  Replication and cytopathic effects of ovine lentivirus strains in alveolar macrophages correlate with in vivo pathogenicity.

Authors:  M D Lairmore; G Y Akita; H I Russell; J C DeMartini
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

4.  Isolates of human immunodeficiency virus type 1 from the brain may constitute a special group of the AIDS virus.

Authors:  C Cheng-Mayer; C Weiss; D Seto; J A Levy
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

5.  Evaluation of an infectivity standard for real-time quality control of human immunodeficiency virus type 1 quantitative micrococulture assays. Participating Laboratories of The AIDS Clinical Trials Group.

Authors:  W A Scott; D Brambilla; E Siwak; C Beatty; J Bremer; R W Coombs; H Farzadegan; S A Fiscus; S M Hammer; F B Hollinger; N Khan; S Rasheed; P S Reichelderfer
Journal:  J Clin Microbiol       Date:  1996-09       Impact factor: 5.948

Review 6.  Clinical use of quantitative molecular methods in studying human immunodeficiency virus type 1 infection.

Authors:  M Clementi; S Menzo; P Bagnarelli; A Valenza; S Paolucci; R Sampaolesi; A Manzin; P E Varaldo
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

Review 7.  Immune dysregulation and CD4+ T cell loss in HIV-1 infection.

Authors:  L Meyaard; F Miedema
Journal:  Springer Semin Immunopathol       Date:  1997

8.  Optimal conditions for recovery of the human immunodeficiency virus from peripheral blood mononuclear cells.

Authors:  B A Castro; C D Weiss; L D Wiviott; J A Levy
Journal:  J Clin Microbiol       Date:  1988-11       Impact factor: 5.948

9.  Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission.

Authors:  A B van't Wout; N A Kootstra; G A Mulder-Kampinga; N Albrecht-van Lent; H J Scherpbier; J Veenstra; K Boer; R A Coutinho; F Miedema; H Schuitemaker
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

10.  HIV infection: what should be considered in approaches for a cure?

Authors:  Jay A Levy; Yves Levy
Journal:  AIDS       Date:  2012-11-13       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.